Johanne Martel-Pelletier

List of Publications by Year
in descending order

217	17,701	11639	14736
papers	citations	70 h-index	127 g-index

272	272	272	13319
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology, 2011, 7, 33-42.	3.5	1,973
2	Osteoarthritis. Nature Reviews Disease Primers, 2016, 2, 16072.	18.1	1,011
3	Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2003, 48, 370-377.	6.7	452
4	Cartilage in normal and osteoarthritis conditions. Best Practice and Research in Clinical Rheumatology, 2008, 22, 351-384.	1.4	424
5	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	1.6	414
6	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2019, 49, 337-350.	1.6	392
7	In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis and Rheumatism, 1997, 40, 1012-1019.	6.7	353
8	Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis and Rheumatism, 1996, 39, 1535-1544.	6.7	338
9	Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1432-1440.	0.5	322
10	Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis and Rheumatism, 2004, 50, 476-487.	6.7	235
11	Metalloproteases and inhibitors in arthritic diseases. Best Practice and Research in Clinical Rheumatology, 2001, 15, 805-829.	1.4	233
12	Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis and Rheumatism, 2000, 43, 1290-1299.	6.7	217
13	Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskeletal Disorders, 2009, 10, 148.	0.8	209
14	Pathophysiology of osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 31-33.	0.6	207
15	Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Research and Therapy, 2005, 8, R21.	1.6	205
16	Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study. Arthritis Research and Therapy, 2007, 9, R74.	1.6	204
17	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritisâ€"From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 2016, 45, S3-S11.	1.6	203
18	Peroxisome proliferator-activated receptor ? activators inhibit interleukin-1?-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis and Rheumatism, 2001, 44, 595-607.	6.7	196

#	Article	IF	Citations
19	Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases, 2016, 75, 37-44.	0.5	194
20	Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis. Arthritis and Rheumatism, 1998, 41, 891-899.	6.7	189
21	Human Osteoarthritic Chondrocytes Possess an Increased Number of Insulin-Like Growth Factor 1 Binding Sites but are Unresponsive to its Stimulation. Arthritis and Rheumatism, 1994, 37, 253-263.	6.7	186
22	Cytokines and their role in the pathophysiology of osteoarthritis. Frontiers in Bioscience - Landmark, 1999, 4, d694.	3.0	186
23	PPARÎ³ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Annals of the Rheumatic Diseases, 2015, 74, 569-578.	0.5	186
24	PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. Journal of Rheumatology, 2002, 29, 3-14.	1.0	182
25	The Induction of Cell Death in Human Osteoarthritis Chondrocytes by Nitric Oxide Is Related to the Production of Prostaglandin E2 Via the Induction of Cyclooxygenase-2. Journal of Immunology, 2000, 165, 3402-3410.	0.4	171
26	Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Annals of the Rheumatic Diseases, 2011, 70, 982-989.	0.5	164
27	Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ. In vitro mimicking effect by transforming growth factor Î². Arthritis and Rheumatism, 1997, 40, 1653-1661.	6.7	163
28	Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 2016, 45, S18-S21.	1.6	157
29	Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis and Rheumatism, 1984, 27, 305-312.	6.7	156
30	Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis and Rheumatism, 1991, 34, 153-163.	6.7	156
31	Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis and Rheumatism, 1983, 26, 63-68.	6.7	152
32	The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis and Rheumatism, 1992, 35, 530-540.	6.7	151
33	Targeting subchondral bone for treating osteoarthritis: what is the evidence?. Best Practice and Research in Clinical Rheumatology, 2010, 24, 51-70.	1.4	147
34	The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone, 2004, 34, 527-538.	1.4	143
35	Computer-aided method for quantification of cartilage thickness and volume changes using mri: validation study using a synthetic model. IEEE Transactions on Biomedical Engineering, 2003, 50, 978-988.	2.5	134
36	Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. Arthritis and Rheumatism, 2009, 60, 1438-1450.	6.7	130

#	Article	IF	Citations
37	Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis and Rheumatism, 1990, 33, 1466-1476.	6.7	126
38	Interleukin-1?-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1? and interleukin-18. Arthritis and Rheumatism, 1999, 42, 1577-1587.	6.7	126
39	Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the pond-nuki dog model of osteoarthritis. Arthritis and Rheumatism, 1983, 26, 866-874.	6.7	124
40	Intraarticular Injections with Methylprednisolone Acetate Reduce Osteoarthritic Lesions in Parallel with Chondrocyte Stromelysin Synthesis in Experimental Osteoarthritis. Arthritis and Rheumatism, 1994, 37, 414-423.	6.7	122
41	Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis. Arthritis and Rheumatism, 1985, 28, 554-561.	6.7	120
42	Machine-learning-based patient-specific prediction models for knee osteoarthritis. Nature Reviews Rheumatology, 2019, 15, 49-60.	3.5	119
43	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 2016, 33, 75-85.	1.3	116
44	Meniscal tear as an osteoarthritis risk factor in a largely non-osteoarthritic cohort: a cross-sectional study. Journal of Rheumatology, 2007, 34, 776-84.	1.0	115
45	In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis and Rheumatism, 2003, 48, 1582-1593.	6.7	112
46	Knee meniscal extrusion in a largely non-osteoarthritic cohort: association with greater loss of cartilage volume. Arthritis Research and Therapy, 2007, 9, R21.	1.6	108
47	Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Annals of the Rheumatic Diseases, 2015, 74, 422-429.	0.5	106
48	Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone, 2011, 49, 559-567.	1.4	103
49	Meniscal extrusion predicts increases in subchondral bone marrow lesions and bone cysts and expansion of subchondral bone in osteoarthritic knees. Rheumatology, 2010, 49, 997-1004.	0.9	101
50	Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 2016, 45, S22-S27.	1.6	101
51	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis. Arthritis and Rheumatism, 2001, 44, 2320-2330.	6.7	100
52	Activation of Peroxisome Proliferator-activated Receptor Î³ Inhibits Interleukin-1Î²-induced Membrane-associated Prostaglandin E2 Synthase-1 Expression in Human Synovial Fibroblasts by Interfering with Egr-1. Journal of Biological Chemistry, 2004, 279, 22057-22065.	1.6	100
53	Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology, 2009, 48, 1482-1490.	0.9	99
54	Automatic Human Knee Cartilage Segmentation From 3-D Magnetic Resonance Images. IEEE Transactions on Biomedical Engineering, 2010, 57, 2699-2711.	2.5	98

#	Article	IF	Citations
55	Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults. Arthritis Research and Therapy, 2010, 12, R222.	1.6	96
56	Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Annals of the Rheumatic Diseases, 2011, 70, 1382-1388.	0.5	93
57	Future therapeutics for osteoarthritis. Bone, 2012, 51, 297-311.	1.4	93
58	Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Research and Therapy, 2007, 9, R117.	1.6	90
59	New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?. Keio Journal of Medicine, 2009, 58, 29-40.	0.5	90
60	Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Research and Therapy, 2006, 8, R26.	1.6	87
61	Discrepancies in Composition and Biological Effects of Different Formulations of Chondroitin Sulfate. Molecules, 2015, 20, 4277-4289.	1.7	84
62	Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis and Rheumatism, 2004, 50, 2521-2530.	6.7	83
63	Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells. Arthritis and Rheumatism, 1999, 42, 1147-1158.	6.7	82
64	Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Co-stimulation of AP-1 and CRE nuclear binding proteins. Journal of Cellular Biochemistry, 1998, 69, 392-413.	1.2	81
65	First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24â€…months: data from the osteoarthritis initiative progression cohort. Annals of the Rheumatic Diseases, 2015, 74, 547-556.	0.5	81
66	Effects of diacerein at the molecular level in the osteoarthritis disease process. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 95-104.	1.2	79
67	Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. Journal of Rheumatology, 2002, 29, 1262-72.	1.0	79
68	Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. Journal of Rheumatology, 2005, 32, 887-95.	1.0	79
69	Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. Arthritis and Rheumatism, 1996, 39, 968-978.	6.7	78
70	Glucocorticoid Receptor Mediated Inhibition of Interleukin-1 Stimulated Neutral Metalloprotease Synthesis in Normal Human Chondrocytes*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 316-326.	1.8	77
71	Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1Î² in the synovium. Annals of the Rheumatic Diseases, 2013, 72, 250-257.	0.5	68
72	Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis and Rheumatism, 2002, 46, 1804-1812.	6.7	64

#	Article	IF	Citations
73	The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide. Arthritis and Rheumatism, 2002, 46, 2637-2647.	6.7	64
74	Human Adult Chondrocytes Express Hepatocyte Growth Factor (HGF) Isoforms but Not HGF: Potential Implication of Osteoblasts on the Presence of HGF in Cartilage. Journal of Bone and Mineral Research, 2003, 18, 1073-1081.	3.1	64
75	IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients. Osteoarthritis and Cartilage, 1996, 4, 263-274.	0.6	63
76	Cloning, sequencing and characterization of the 5â€²-flanking region of the human collagenase-3 gene. Biochemical Journal, 1997, 323, 13-16.	1.7	63
77	Adult Cartilage-Specific Peroxisome Proliferatorâ€“Activated Receptor Gamma Knockout Mice Exhibit the Spontaneous Osteoarthritis Phenotype. American Journal of Pathology, 2013, 182, 1099-1106.	1.9	63
78	NFAT3 and TGF-Î²/SMAD3 regulate the expression of miR-140 in osteoarthritis. Arthritis Research and Therapy, 2013, 15, R197.	1.6	62
79	Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Research and Therapy, 2007, 9, R121.	1.6	61
80	Endogenous Prostaglandin E2 and Insulin-like Growth Factor 1 Can Modulate the Levels of Parathyroid Hormone Receptor in Human Osteoarthritic Osteoblasts. Journal of Bone and Mineral Research, 2001, 16, 713-721.	3.1	59
81	Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Modern Rheumatology, 2004, 14, 197-204.	0.9	59
82	Oral treatment with PD-0200347, an ?2? ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis and Rheumatism, 2005, 52, 488-500.	6.7	59
83	Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions. JAMA - Journal of the American Medical Association, 2020, 323, 1456.	3.8	59
84	Effects of tenidap on canine experimental osteoarthritis i. morphologic and metalloprotease analysis. Arthritis and Rheumatism, 1995, 38, 1290-1303.	6.7	58
85	Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis and Rheumatism, 1999, 42, 2112-2122.	6.7	58
86	Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI. Annals of the Rheumatic Diseases, 2010, 69, 2118-2124.	0.5	58
87	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: Further Studies on Histologic and Subcellular Distribution. Arthritis and Rheumatism, 1984, 27, 193-199.	6.7	56
88	Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B4 in osteoarthritic chondrocytes: Role of transforming growth factor ? and eicosanoids. Arthritis and Rheumatism, 2004, 50, 3925-3933.	6.7	56
89	The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Research and Therapy, 2005, 7, R1091.	1.6	56
90	Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone, 2006, 38, 333-341.	1.4	56

#	Article	IF	Citations
91	Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: Influence of osteotropic factors. Bone, 2008, 43, 284-291.	1.4	55
92	Inhibition of interleukinâ€1Î²â€“induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D₂. Arthritis and Rheumatism, 2008, 58, 3530-3540.	6.7	53
93	Association of cartilageâ€specific deletion of peroxisome proliferatorâ€“activated receptor Î³ with abnormal endochondral ossification and impaired cartilage growth and development in a murine model. Arthritis and Rheumatism, 2012, 64, 1551-1561.	6.7	53
94	Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. Journal of Rheumatology, 2002, 29, 546-53.	1.0	52
95	Cartilage degradation by neutral proteoglycanases in experimental osteoarthritis. Suppression by steroids. Arthritis and Rheumatism, 1985, 28, 1393-1401.	6.7	51
96	Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Arthritis and Rheumatism, 2008, 58, 3820-3830.	6.7	51
97	The levels of the adipokines adipsin and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: apost hocanalysis. Rheumatology, 2016, 55, 680-688.	0.9	51
98	The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study. Arthritis Research and Therapy, 2014, 16, 507.	1.6	50
99	A fully automated human knee 3D MRI bone segmentation using the ray casting technique. Medical and Biological Engineering and Computing, 2011, 49, 1413-1424.	1.6	49
100	Subchondral bone morphological and biochemical alterations in osteoarthritis. Osteoarthritis and Cartilage, 1999, 7, 321-322.	0.6	48
101	Variable Effects of 3 Different Chondroitin Sulfate Compounds on Human Osteoarthritic Cartilage/Chondrocytes: Relevance of Purity and Production Process. Journal of Rheumatology, 2010, 37, 656-664.	1.0	47
102	Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: Involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade. Arthritis and Rheumatism, 2001, 44, 73-84.	6.7	46
103	Human Hip Joint Cartilage: MRI Quantitative Thickness and Volume Measurements Discriminating Acetabulum and Femoral Head. IEEE Transactions on Biomedical Engineering, 2008, 55, 2731-2740.	2.5	46
104	Endothelin 1 promotes osteoarthritic cartilage degradation via matrix metalloprotease 1 and matrix metalloprotease 13 induction. Arthritis and Rheumatism, 2003, 48, 2855-2864.	6.7	45
105	Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Modern Rheumatology, 2004, 14, 197-204.	0.9	45
106	Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis and Rheumatism, 1993, 36, 1517-1527.	6.7	42
107	Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblasts. Arthritis Research and Therapy, 2006, 8, R177.	1.6	42
108	Expression of c-fos, c-jun,jun-B, metallothionein and metalloproteinase genes in human chondrocyte. FEBS Letters, 1992, 306, 169-172.	1.3	39

#	Article	IF	Citations
109	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: some biochemical characteristic. Arthritis and Rheumatism, 1984, 27, 186-192.	6.7	38
110	Extracellular localization of galectin-3 has a deleterious role in joint tissues. Arthritis Research and Therapy, 2007, 9, R20.	1.6	38
111	The unfolded protein response genes in human osteoarthritic chondrocytes: PERK emerges as a potential therapeutic target. Arthritis Research and Therapy, 2016, 18, 172.	1.6	38
112	Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Research and Therapy, 2016, 18, 256.	1.6	38
113	Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Research and Therapy, 2018, 20, 250.	1.6	36
114	The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein. Arthritis Research and Therapy, 2006, 8, R181.	1.6	35
115	Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging. Arthritis Research and Therapy, 2010, 12, R173.	1.6	35
116	Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis. PLoS ONE, 2017, 12, e0175565.	1.1	35
117	New thoughts on the pathophysiology of osteoarthritis: One more step toward new therapeutic targets. Current Rheumatology Reports, 2006, 8, 30-36.	2.1	34
118	Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts. Bone, 2009, 44, 1143-1150.	1.4	34
119	Analgesic efficacy of an oral transmucosal spray formulation of meloxicam alone or in combination with tramadol in cats with naturally occurring osteoarthritis. Veterinary Anaesthesia and Analgesia, 2016, 43, 643-651.	0.3	34
120	Activation of The Phosphatidylcholine to Lysophosphatidylcholine Pathway Is Associated with Osteoarthritis Knee Cartilage Volume Loss Over Time. Scientific Reports, 2019, 9, 9648.	1.6	34
121	Is osteoarthritis a disease involving only cartilage or other articular tissues?. Eklem Hastaliklari Ve Cerrahisi = Joint Diseases & Related Surgery, 2010, 21, 2-14.	2.5	34
122	Increased insulin-like growth factor 1 production by human osteoarthritic chondrocytes is not dependent on growth hormone action. Arthritis and Rheumatism, 1995, 38, 413-419.	6.7	33
123	Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. Arthritis Research and Therapy, 2009, 11, R119.	1.6	32
124	In vivo boneâ€specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis. Arthritis and Rheumatism, 2012, 64, 3614-3625.	6.7	31
125	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs and Aging, 2015, 32, 525-535.	1.3	31
126	A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. Aging Clinical and Experimental Research, 2019, 31, 19-30.	1.4	31

#	Article	IF	Citations
127	Immunological analysis of proteoglycan structural changes in the early stage of experimental osteoarthritic canine cartilage lesions. Journal of Orthopaedic Research, 1992, 10, 511-523.	1.2	30
128	Proteinase-activated Receptor-2 Gene Disruption Limits the Effect of Osteoarthritis on Cartilage in Mice: A Novel Target in Joint Degradation. Journal of Rheumatology, 2011, 38, 911-920.	1.0	30
129	Longâ€Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Sixâ€Year Followup Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2016, 68, 1560-1566.	1.5	30
130	Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study. Arthritis Research and Therapy, 2017, 19, 169.	1.6	30
131	Total Knee Replacement as a Knee Osteoarthritis Outcome. Cartilage, 2013, 4, 219-226.	1.4	29
132	Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis and Rheumatism, 1997, 40, 284-294.	6.7	28
133	The longitudinal relationship between changes in body weight and changes in medial tibial cartilage, and pain among community-based adults with and without meniscal tears. Annals of the Rheumatic Diseases, 2014, 73, 1652-1658.	0.5	28
134	Magnetic Resonance Imagingâ€“Assessed Vastus Medialis Muscle Fat Content and Risk for Knee Osteoarthritis Progression: Relevance From a Clinical Trial. Arthritis Care and Research, 2015, 67, 1406-1415.	1.5	26
135	An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology, 2020, 59, 3858-3868.	0.9	26
136	Evoked Temporal Summation in Cats to Highlight Central Sensitization Related to Osteoarthritis-Associated Chronic Pain: A Preliminary Study. PLoS ONE, 2014, 9, e97347.	1.1	26
137	Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial. Arthritis Research and Therapy, 2015, 17, 82.	1.6	25
138	Identification of the most important features of knee osteoarthritis structural progressors using machine learning methods. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093346.	1.2	25
139	New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?. Expert Opinion on Pharmacotherapy, 2013, 14, 2059-2077.	0.9	24
140	Assessment of Cartilage Changes Over Time in Knee Osteoarthritis Diseaseâ€Modifying Osteoarthritis Drug Trials Using Semiquantitative and Quantitative Methods: Pros and Cons. Arthritis Care and Research, 2013, 65, 686-694.	1.5	24
141	A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199325.	1.2	24
142	Human rheumatoid arthritic cartilage and its neutral proteoglycan-degrading proteases. The effects of antirheumatic drugs. Arthritis and Rheumatism, 1985, 28, 405-412.	6.7	23
143	Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. Arthritis Research and Therapy, 2009, 10, R146.	1.6	21
144	Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort. Seminars in Arthritis and Rheumatism, 2015, 45, 257-267.	1.6	21

#	Article	IF	Citations
145	Mesenchymal Stromal Cell Immunology for Efficient and Safe Treatment of Osteoarthritis. Frontiers in Cell and Developmental Biology, 2020, 8, 567813.	1.8	21
146	Machine Learningâ€“Based Individualized Survival Prediction Model for Total Knee Replacement in Osteoarthritis: Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2021, 73, 1518-1527.	1.5	21
147	Identification in human osteoarthritic chondrocytes of proteins binding to the novel regulatory site AGRE in the human matrix metalloprotease 13 proximal promoter. Arthritis and Rheumatism, 2006, 54, 2471-2480.	6.7	20
148	Natural history and clinical significance of meniscal tears over 8Âyears in a midlife cohort. BMC Musculoskeletal Disorders, 2016, 17, 4.	0.8	20
149	A Novel Negative Regulatory Element in the Human Collagenase-3 Proximal Promoter Region. Biochemical and Biophysical Research Communications, 2002, 291, 1151-1159.	1.0	19
150	[18F]-fluorodeoxyglucose positron emission tomography of the cat brain: A feasibility study to investigate osteoarthritis-associated pain. Veterinary Journal, 2015, 204, 299-303.	0.6	19
151	Clinical diagnosis of partial or complete anterior cruciate ligament tears using patients' history elements and physical examination tests. PLoS ONE, 2018, 13, e0198797.	1.1	19
152	Interleukin-1Î² induction of tissue inhibitor of metalloproteinase (TIMP-1) is functionally antagonized by prostaglandin E2 in human synovial fibroblasts. Journal of Cellular Biochemistry, 1995, 57, 619-629.	1.2	18
153	Exploring determinants predicting response to intra-articular hyaluronic acid treatment in symptomatic knee osteoarthritis: 9-year follow-up data from the Osteoarthritis Initiative. Arthritis Research and Therapy, 2018, 20, 40.	1.6	18
154	Expression of Peroxisome Proliferator-activated Receptors Î±, Î², Î³, and H- and L-Prostaglandin D Synthase During Osteoarthritis in the Spontaneous Hartley Guinea Pig and Experimental Dog Models. Journal of Rheumatology, 2013, 40, 877-890.	1.0	17
155	Refinement of the Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians: detection of naturally occurring osteoarthritis in laboratory cats. Journal of Feline Medicine and Surgery, 2018, 20, 728-740.	0.6	17
156	High in vivo levels of adipsin lead to increased knee tissue degradation in osteoarthritis: data from humans and animal models. Rheumatology, 2018, 57, 1851-1860.	0.9	17
157	Mass spectrometry-based proteomics identify novel serum osteoarthritis biomarkers. Arthritis Research and Therapy, 2022, 24, .	1.6	17
158	A single injection of anakinra for treating knee OA?. Nature Reviews Rheumatology, 2009, 5, 363-364.	3.5	16
159	Characterization of opticin digestion by proteases involved in osteoarthritis development. Joint Bone Spine, 2014, 81, 137-141.	0.8	16
160	Impact of oral osteoarthritis therapyÂusage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort. Arthritis Research and Therapy, 2018, 20, 172.	1.6	16
161	Intra-articular corticosteroid knee injection induces a reduction in meniscal thickness with no treatment effect on cartilage volume: a caseâ€“control study. Scientific Reports, 2020, 10, 13789.	1.6	16
162	Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. Journal of Rheumatology, 2006, 33, 1176-83.	1.0	16

#	Article	IF	Citations
163	Calphostin C induces AP1 synthesis and AP1-dependent c-jun transactivation in normal human chondrocytes independent of protein kinase c-? inhibition: Possible role for c-jun N-terminal kinase. Journal of Cellular Biochemistry, 2000, 76, 290-302.	1.2	15
164	Validity of Combining History Elements and Physical Examination Tests to Diagnose Patellofemoral Pain. Archives of Physical Medicine and Rehabilitation, 2018, 99, 607-614.e1.	0.5	15
165	Serum lysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic responders to symptomatic drugs in knee osteoarthritis patients. Arthritis Research and Therapy, 2019, 21, 224.	1.6	13
166	Serum adipokines/related inflammatory factors and ratios as predictors of infrapatellar fat pad volume in osteoarthritis: Applying comprehensive machine learning approaches. Scientific Reports, 2020, 10, 9993.	1.6	13
167	Brachystemma calycinumD. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-9.	0.5	12
168	Spinal neuropeptide modulation, functional assessment and cartilage lesions in a monosodium iodoacetate rat model of osteoarthritis. Neuropeptides, 2017, 65, 56-62.	0.9	12
169	Diacerein-containing products: same risk of diarrhoea?. Aging Clinical and Experimental Research, 2018, 30, 411-412.	1.4	12
170	A reliable time-series method for predicting arthritic disease outcomes: New step from regression toward a nonlinear artificial intelligence method. Computer Methods and Programs in Biomedicine, 2020, 189, 105315.	2.6	12
171	Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial. Rheumatology, 2017, 56, 989-998.	0.9	11
172	Exacerbation of Agingâ€Associated and Instabilityâ€Induced Murine Osteoarthritis With Deletion of D Prostanoid Receptor 1, a Prostaglandin D₂ Receptor. Arthritis and Rheumatology, 2017, 69, 1784-1795.	2.9	11
173	Measuring Disease Progression in Osteoarthritis. Current Treatment Options in Rheumatology, 2016, 2, 97-110.	0.6	10
174	Change in knee structure and change in tibiofemoral joint space width: a five year longitudinal populationâ€“based study. BMC Musculoskeletal Disorders, 2016, 17, 25.	0.8	9
175	Cartilage-specific deletion of ephrin-B2 in mice results in early developmental defects and an osteoarthritis-like phenotype during aging in vivo. Arthritis Research and Therapy, 2016, 18, 65.	1.6	9
176	The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms. Rheumatology, 2021, 60, 2791-2800.	0.9	9
177	Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells. World Journal of Stem Cells, 2020, 12, 1474-1491.	1.3	9
178	Metabolic activity of osteoblasts from periprosthetic trabecular bone in failed total hip arthroplasties and osteoarthritis as markers of osteolysis and loosening. Journal of Rheumatology, 2002, 29, 1437-45.	1.0	9
179	New Insights into the Major Pathophysiological Processes Responsible for the Development of Osteoarthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 6-8.	1.6	8
180	Responsiveness of Magnetic Resonance Imaging-derived Measures Over 2.7 Years. Journal of Rheumatology, 2014, 41, 2060-2067.	1.0	8

#	Article	IF	Citations
181	The inÂVivo Effect of Prophylactic Subchondral Bone Protection of Osteoarthritic Synovial Membrane in Bone-Specific Ephb4-Overexpressing Mice. American Journal of Pathology, 2015, 185, 335-346.	1.9	8
182	In vivo effect of opticin deficiency in cartilage in a surgically induced mouse model of osteoarthritis. Scientific Reports, 2018, 8, 457.	1.6	8
183	Role of Lipocalinâ€Type Prostaglandin D Synthase in Experimental Osteoarthritis. Arthritis and Rheumatology, 2020, 72, 1524-1533.	2.9	8
184	In vivo protective effect of adipsin-deficiency on spontaneous knee osteoarthritis in aging mice. Aging, 2020, 12, 2880-2896.	1.4	8
185	A Machine Learning Model to Predict Knee Osteoarthritis Cartilage Volume Changes over Time Using Baseline Bone Curvature. Biomedicines, 2022, 10, 1247.	1.4	8
186	Correlation Between Changes in Global Knee Structures Assessed by Magnetic Resonance Imaging and Radiographic Osteoarthritis Changes Over Ten Years in a Midlife Cohort. Arthritis Care and Research, 2016, 68, 958-964.	1.5	7
187	L-PGDS deficiency accelerated the development of naturally occurring age-related osteoarthritis. Aging, 2020, 12, 24778-24797.	1.4	7
188	A fully automated system for quantification of knee bone marrow lesions using MRI and the osteoarthritis initiative cohort. Journal of Biomedical Graphics and Computing, 2012, 3, .	0.2	6
189	Does cartilage volume measurement or radiographic osteoarthritis at baseline independently predict ten-year cartilage volume loss?. BMC Musculoskeletal Disorders, 2016, 17, 54.	0.8	6
190	Diagnostic Validity of Combining History Elements and Physical Examination Tests for Traumatic and Degenerative Symptomatic Meniscal Tears. PM and R, 2018, 10, 472-482.	0.9	5
191	Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort. Journal of Biomedical Science and Engineering, 2013, 06, 337-345.	0.2	5
192	Osteoarthritis of the Knee: Report of a Task Force of the International League of Associations for Rheumatology and the Osteoarthritis Research Society. Journal of the American Geriatrics Society, 1997, 45, 850-852.	1.3	4
193	Animal models of osteoarthritis. , 2015, , 1454-1461.		4
194	Coxofemoral joint kinematics using video fluoroscopic images of treadmill-walking cats: development of a technique to assess osteoarthritis-associated disability. Journal of Feline Medicine and Surgery, 2015, 17, 134-143.	0.6	4
195	A continuous data driven translational model to evaluate effectiveness of population-level health interventions: case study, smoking ban in public places on hospital admissions for acute coronary events. Journal of Translational Medicine, 2020, 18, 466.	1.8	4
196	Common Biochemical and Magnetic Resonance Imaging Biomarkers of Early Knee Osteoarthritis and of Exercise/Training in Athletes: A Narrative Review. Diagnostics, 2021, 11, 1488.	1.3	4
197	Transcriptional induction of cyclooxygenaseâ€2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Coâ€stimulation of APâ€1 and CRE nuclear binding proteins. Journal of Cellular Biochemistry, 1998, 69, 392-413.	1.2	4
198	Osteoarthritic pain model influences functional outcomes and spinal neuropeptidomics: A pilot study in female rats. Canadian Journal of Veterinary Research, 2019, 83, 133-141.	0.2	4

#	Article	IF	Citations
199	Estrogenic impregnation alters pain expression: analysis through functional neuropeptidomics in a surgical rat model of osteoarthritis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 703-715.	1.4	4
200	Quantitative imaging of the structural changes of osteoarthritis: An exciting challenge for the new millennium. Current Rheumatology Reports, 2001, 3, 465-466.	2.1	3
201	Drug/Agent Treatments for Osteoarthritis: Present and Future. , 2015, , 191-210.		3
202	How Do MRI-Detected Subchondral Bone Marrow Lesions (BMLs) on Two Different MRI Sequences Correlate with Clinically Important Outcomes?. Calcified Tissue International, 2018, 103, 131-143.	1.5	3
203	Associations of Joint Line Tenderness and Patellofemoral Grind With Longâ€Term Knee Joint Outcomes: Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2020, 72, 778-786.	1.5	3
204	Viewpoint on Time Series and Interrupted Time Series Optimum Modeling for Predicting Arthritic Disease Outcomes. Current Rheumatology Reports, 2020, 22, 27.	2.1	3
205	Initial derivation of diagnostic clusters combining history elements and physical examination tests for symptomatic knee osteoarthritis. Musculoskeletal Care, 2018, 16, 370-379.	0.6	2
206	Associations of blood pressure and arterial stiffness with knee cartilage volume in patients with knee osteoarthritis. Rheumatology, 2021, 60, 4748-4754.	0.9	2
207	The relationship between knee loading during gait and cartilage thickness in nontraumatic and posttraumatic knee osteoarthritis. Journal of Orthopaedic Research, 2022, 40, 1778-1786.	1.2	2
208	An Open Debate on the Morphological Measurement Methodologies of the Infrapatellar Fat Pad to Determine Its Association with the Osteoarthritis Process. Current Rheumatology Reports, 2022, 24, 76-80.	2.1	2
209	Vastus medialis intramuscular fat is associated with reduced quadriceps strength, but not knee osteoarthritis severity. Clinical Biomechanics, 2022, 96, 105669.	0.5	2
210	Influence of Tumor Necrosis Factor Î±, Parathyroid Hormone, and Vitamin D₃ on Modulation of the RANKL2 Isoform. Cartilage, 2012, 3, 100-103.	1.4	1
211	Reply. Arthritis Care and Research, 2018, 70, 168-168.	1.5	1
212	Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested caseâ€“control study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210913.	1.2	1
213	Clinical relevance of MRI knee abnormalities in Australian rules football players: a longitudinal study. BMJ Open Sport and Exercise Medicine, 2021, 7, e001097.	1.4	0
214	Valproic acid suppresses interleukinâ€1Î²â€induced microsomal prostaglandin E2 Synthaseâ€1 expression in chondrocytes. FASEB Journal, 2011, 25, 945.14.	0.2	0
215	Prostaglandin D2 enhances interleukin â€1Î²â€induced cyclooxygenaseâ€2 expression in osteoarthritic cartilage. FASEB Journal, 2011, 25, 945.15.	0.2	0
216	Interleukinâ€1â€induced cyclooxygenaseâ€2 and inducible nitric oxide synthase expression in human OA chondrocytes is associated with histone H3K4 methylation. FASEB Journal, 2011, 25, 945.4.	0.2	0

#	Article	IF	Citations
217	Egrâ€1 mediates the suppressive effect of ILâ€1 on PPARg expression in human OA chondrocytes. FASEB Journal, 2012, 26, lb80.	0.2	0